Study suggests tumour microenvironments could predict cancer progression
NSCLC is the most common type of lung cancer and is responsible for up to 85% of all cases
Read Moreby Jen Brogan | Apr 12, 2024 | News | 0
NSCLC is the most common type of lung cancer and is responsible for up to 85% of all cases
Read Moreby Jen Brogan | Apr 3, 2024 | News | 0
The third most common and serious form of cancer affects over 43,000 people every year in the UK
Read Moreby Jen Brogan | Mar 1, 2024 | News | 0
TMR-CT will help doctors select treatment and predict the spread of lung cancer in patients
Read Moreby Jen Brogan | Feb 13, 2024 | News | 0
The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359
Read Moreby Jen Brogan | Jan 11, 2024 | News | 0
The diagnostic system can deliver particles to the lungs via aerosol or a nebuliser
Read Moreby Jen Brogan | Dec 18, 2023 | News | 0
Earlier diagnosis could increase patient survival rates by five years or more
Read Moreby Jen Brogan | Dec 7, 2023 | News | 0
The disease is one of the leading causes of cancer deaths in the UK
Read Moreby Jen Brogan | Nov 7, 2023 | News | 0
Lung cancer is currently the leading cause of cancer deaths in the UK
Read Moreby Jen Brogan | Nov 1, 2023 | News | 0
The AI tools to be deployed will help NHS staff to analyse X-rays and CT scans
Read Moreby John Pinching | Aug 7, 2023 | News | 0
A combination of zipalertinib and chemotherapy will be evaluated as a treatment for adults
Read Moreby John Pinching | Mar 10, 2023 | News | 0
Positive results emerge from AEGEAN phase 3 trial for patients with resectable non-small cell lung cancer
Read Moreby Fleur Jeffries | Dec 22, 2022 | News | 0
Study uses carious drug combinations to increase survival among lung cancer patients
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479